ABSTRACT: The frequency of lymphogranuloma venereum or invasive Chlamydia trachomatis infection with serovar L1, L2, or L3 is unknown in the United States. While no diagnostic test is commercially available, we used a laboratory-developed test and detected lymphogranuloma venereum-associated serovar L2 in 14% of 132 remnant C. trachomatis-positive rectal swabs.
ABSTRACT: The frequency of lymphogranuloma venereum or invasive Chlamydia trachomatis infection with serovar L1, L2, or L3 is unknown in the United States. While no diagnostic test is commercially available, we used a laboratory-developed test and detected lymphogranuloma venereum-associated serovar L2 in 14% of 132 remnant C. trachomatis-positive rectal swabs.
Authors: Preeti Pathela; Kelly Jamison; John Kornblum; Tammy Quinlan; Tanya A Halse; Julia A Schillinger Journal: Sex Transm Dis Date: 2019-02 Impact factor: 2.830
Authors: Byron E Batteiger; Raymond Wan; James A Williams; Linda He; Arissa Ma; J Dennis Fortenberry; Deborah Dean Journal: Emerg Infect Dis Date: 2014-11 Impact factor: 6.883
Authors: Deborah Dean; William J Bruno; Raymond Wan; João P Gomes; Stéphanie Devignot; Tigist Mehari; Henry J C de Vries; Servaas A Morré; Garry Myers; Timothy D Read; Brian G Spratt Journal: Emerg Infect Dis Date: 2009-09 Impact factor: 6.883
Authors: Evonne N Woodson; Samantha S Katz; Sheree S Mosley; Damien C Danavall; Katherine E Bowden; Kai-Hua Chi; Brian H Raphael Journal: Diagn Microbiol Infect Dis Date: 2021-08-27 Impact factor: 2.803